Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Solabegron Formulations in Healthy Males
NCT02938507Phase 1Completed
- Sponsor
- Velicept Therapeutics
- Start
- Oct 2016
- Primary completion
- Dec 2016
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, single-blind trial of Solabegron in overactive bladder (OAB) (2 arms), sponsored by Velicept Therapeutics. Primary endpoint: Maximum observed plasma drug concentration at 24 hours. Started Oct 2016; status: completed.
02
Drugs
Solabegron
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on NCT02938507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02938507.